Neon Therapeutics

    OverviewSuggest Edit

    We have assembled a team of world experts in cancer immunotherapy to develop therapies that target abnormal proteins called neoantigens, which are produced by cancer cells. Our programs are designed to leverage multiple facets of the immune response to elicit potent immune attack of tumors, with the aim of providing durable response to patients in need.

    At Neon we are committed to advancing the field of cancer immunotherapy by investing in research in neoantigen biology, epitope prediction, cancer bioinformatics, personalized therapies and advanced immune profiling of cancer patients.

    Headquartered in Cambridge, MA., Neon Therapeutics is a private company launched in 2015 with $55 million in Series A venture capital financing from Third Rock Ventures, Clal Biotechnology Industries and Access Industries.

    TypePublic
    Founded2015
    HQCambridge, MA, US
    Websiteneontherapeutics.com
    Employee Ratings4.5

    Latest Updates

    Employees (est.) (Dec 2019)71(-30%)
    Cybersecurity ratingFMore

    Key People/Management at Neon Therapeutics

    Hugh ODowd

    Hugh ODowd

    Chief Executive Officer
    Ed Fritsch

    Ed Fritsch

    Founder
    Richard Gaynor

    Richard Gaynor

    President of Research & Development
    Robert Bazemore

    Robert Bazemore

    President and CEO, Epizyme
    Kelledy Manson

    Kelledy Manson

    Vice President of Product Development
    Cary Pfeffer

    Cary Pfeffer

    Chairman; Partner, Third Rock Ventures
    Show more

    Neon Therapeutics Office Locations

    Neon Therapeutics has an office in Cambridge
    Cambridge, MA, US (HQ)
    40 Erie St #110
    Show all (1)

    Neon Therapeutics Financials and Metrics

    Neon Therapeutics Revenue

    USD

    Net income (Q1, 2020)

    (16.6m)

    EBIT (Q1, 2020)

    (16.7m)

    Cash (31-Mar-2020)

    15.0m
    Annual
    USDFY, 2018FY, 2019

    General and administrative expense

    18.3m21.4m

    R&D expense

    60.4m59.7m

    Operating expense total

    78.7m81.1m

    EBIT

    (78.7m)(81.1m)
    Quarterly
    USDQ2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

    General and administrative expense

    4.3m4.6m5.4m5.6m5.1m7.2m

    R&D expense

    14.8m14.4m16.2m16.7m14.1m9.4m

    Operating expense total

    19.1m19.1m21.6m22.3m19.3m16.7m

    EBIT

    (19.1m)(19.1m)(21.6m)(22.3m)(19.3m)(16.7m)
    Annual
    USDFY, 2018FY, 2019

    Cash

    52.7m29.4m

    Prepaid Expenses

    2.1m1.8m

    Current Assets

    105.4m31.2m

    PP&E

    8.2m7.1m
    Quarterly
    USDQ2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

    Cash

    130.8m60.8m49.3m46.3m44.3m15.0m

    Prepaid Expenses

    1.6m2.3m2.3m2.0m2.0m2.0m

    Current Assets

    140.2m124.0m83.6m63.0m46.3m17.0m

    PP&E

    7.6m8.0m8.5m8.0m7.7m6.7m
    Annual
    USDFY, 2018FY, 2019

    Net Income

    (76.9m)(79.8m)

    Depreciation and Amortization

    1.6m

    Accounts Payable

    2.0m(2.3m)

    Cash From Operating Activities

    (63.4m)(73.4m)
    Quarterly
    USDQ2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

    Net Income

    (35.4m)(53.8m)(21.0m)(43.0m)(61.9m)(16.6m)

    Depreciation and Amortization

    692.0k1.1m415.0k1.3m

    Accounts Payable

    (1.1m)490.0k(1.3m)(2.1m)1.3m

    Cash From Operating Activities

    (29.6m)(45.5m)(21.2m)(41.2m)(57.9m)(14.3m)
    USDQ2, 2018

    Financial Leverage

    1.1 x
    Show all financial metrics

    Neon Therapeutics Cybersecurity Score

    Cybersecurity ratingPremium dataset

    F

    56/100

    SecurityScorecard logo

    Neon Therapeutics Environment, Social & Governance (ESG) Ratings

    CSRHub ESG ratingPremium dataset

    40-49

    out of 100

    CSRHub logo

    Neon Therapeutics Online and Social Media Presence

    Embed Graph

    Neon Therapeutics News and Updates

    SHAREHOLDER ALERT: WeissLaw LLP Investigates Neon Therapeutics, Inc.

    NEW YORK, April 10, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Neon Therapeutics, Inc. ("NTGN" or the "Company") (NASDAQ: NTGN) in connection with the proposed acquisition of the Company...

    Thinking about buying stock in BioNTech, Chesapeake Energy, Digital Realty, Neon Therapeutics, or Waitr?

    NEW YORK, March 18, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BNTX, CHK, DLR, NTGN, and WTRH. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

    Neon Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update

    CAMBRIDGE, Mass., March 02, 2020 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq: NTGN) today reported financial results for the fourth quarter and full-year ended December 31, 2019 and provided a business update.

    Precision Medicine Market: Industry Analysis and Detailed Profiles of Neon Therapeutics, Moderna, Inc, Merck & Co., Inc, Bayer AG, PERSONALIS INC, GENOCEA BIOSCIENCES, INC | Data Bridge Market Research

    SAN FRANCISCO, Dec. 6, 2019 /PRNewswire/ -- The perfect way to anticipate what future holds is to understand the trend today and hence Global Precision Medicine Market report has been structured by chewing over numerous fragments of the present and upcoming market scenario. The report...

    Shares of Neon Therapeutics rise on restructuring plans

    Shares of Neon Therapeutics were up 19% in after-hours trading Wednesday after the company announced a corporate restructuring that includes cutting 24% of its workforce. Neon, which employs about 100 workers, now plans to focus on developing T-cell therapies and is halting new spending on its canc…

    Neon Therapeutics Reports First Quarter 2019 Financial Results and Provides Clinical Update

    Advancing a class-leading position in neoantigen-based therapies with ongoing progress across its multiple clinical-stage programs, pre-clinical pipeline and bioinformatics engine
    Show more

    Neon Therapeutics Blogs

    Neon Therapeutics Submits European Clinical Trial Authorization Application for Personal Neoantigen-Targeted T Cell Therapy NEO-PTC-01

    Neon Therapeutics Submits European Clinical Trial Authorization Application for Personal Neoantigen-Targeted T Cell Therapy NEO-PTC-01 Content Import Wed, 12/18/2019 - 08:01 Neon Therapeutics Submits European Clinical Trial Authorization Application for Personal Neoantigen-Targeted T Cell …

    Neon Therapeutics Announces New Strategic Focus on Novel T Cell Programs

    Neon Therapeutics Announces New Strategic Focus on Novel T Cell Programs Content Import Wed, 11/20/2019 - 16:06 Neon Therapeutics Announces New Strategic Focus on Novel T Cell Programs November 20, 2019 at 4:05 PM EST This release is a backfill from a News Wir…

    Neon Therapeutics Reports Third Quarter 2019 Financial Results and Recent Highlights

    Neon Therapeutics Reports Third Quarter 2019 Financial Results and Recent Highlights Content Import Tue, 11/12/2019 - 07:01 Neon Therapeutics Reports Third Quarter 2019 Financial Results and Recent Highlights November 12, 2019 at 7:00 AM EST This release is a …

    Neon Therapeutics Announces Updated Data Presented at Society for Immunotherapy of Cancer (SITC) Annual Meeting

    Neon Therapeutics Announces Updated Data Presented at Society for Immunotherapy of Cancer (SITC) Annual Meeting Content Import Fri, 11/08/2019 - 07:00 Neon Therapeutics Announces Updated Data Presented at Society for Immunotherapy of Cancer (SITC) Annual Meeting November 8, …

    Neon Therapeutics Reports Second Quarter 2019 Financial Results

    Planning to present more detailed data from NT-001 clinical trial evaluating NEO-PV-01 in advanced or metastatic melanoma, non-small cell lung and bladder cancers at an upcoming medical society meeting Announces U.S. Food & Drug Administration ( FDA ) clearance of Neon’s Investigational New Drug

    Neon Therapeutics’ Personal Neoantigen Vaccine Study Demonstrates Prolonged Progression-Free Survival in Advanced or Metastatic Melanoma, Non-Small Cell Lung and Bladder Cancers

    Neon Therapeutics’ Personal Neoantigen Vaccine Study Demonstrates Prolonged Progression-Free Survival in Advanced or Metastatic Melanoma, Non-Small Cell Lung and Bladder Cancers Content Import Mon, 07/15/2019 - 06:01 Neon Therapeutics’ Personal Neoantigen Vaccine Study Demonstrates Prolong…
    Show more

    Neon Therapeutics Frequently Asked Questions

    • When was Neon Therapeutics founded?

      Neon Therapeutics was founded in 2015.

    • Who are Neon Therapeutics key executives?

      Neon Therapeutics's key executives are Hugh ODowd, Ed Fritsch and Richard Gaynor.

    • How many employees does Neon Therapeutics have?

      Neon Therapeutics has 71 employees.

    • Who are Neon Therapeutics competitors?

      Competitors of Neon Therapeutics include ImmusanT, Bionuclear and HEALI.

    • Where is Neon Therapeutics headquarters?

      Neon Therapeutics headquarters is located at 40 Erie St #110, Cambridge.

    • Where are Neon Therapeutics offices?

      Neon Therapeutics has an office in Cambridge.

    • How many offices does Neon Therapeutics have?

      Neon Therapeutics has 1 office.